Breast Cancer
Conditions
Keywords
HR+/HER2+ Breast cancer, Neoadjuvant therapy, pyrotinib
Brief summary
Due to neoadjuvant therapy with trastuzumab and pertuzumab is less effective for HR+/HER2+ breast cancer, and the PHEDRA Clinical Study subgroup analysis showed that the addition of pyrotinib to trastuzumab more than doubled pCR rates in HR+/HER2+ patients. our research group proposed a hypothesis that pyrotinib may be more advantageous for HR+/HER2+ breast cancer. Therefore, our center intends to carry out a multi-center, randomized controlled, prospective clinical study to compare the efficacy of pyrotinib or pertuzumab combined with docetaxel, carboplatin and trastuzumab in neoadjuvant therapy for patients with HR+/HER2+ breast cancer, and to conduct a comparative study on the safety.
Detailed description
Different anti-HER2-targeting drugs act on different parts and types of HER2 molecules, so their mechanisms and effects are different. Trastuzumab and pertuzumab are the most commonly used anti-HER2 targeting drugs, which target the extracellular segment of THE HER2 molecule. The major guidelines recommend the use of trastuzumab and pertuzumab in the use of neoadjuvant therapy with a two-target regimen. Another commonly used class of anti-HER2-targeting drugs are Tyrosine kinase inhibitors (TKI), which target the intracellular segment of the HER2 molecule. Not only that, take domestically developed pyrotinib as an example, in addition to targeting HER2, it also targets HER1 and HER4. Because of the different mechanisms of action, TKI is still effective in patients with trastuzumab and/or pertuzumab resistant relapsing metastasis. To investigate the efficacy of pyrotinib in neoadjuvant therapy, a prospective, randomized, double-blind, multicenter clinical trial, the PHEDRA Clinical Study, was conducted in China. Results presented at the 2021 ASCO Meeting showed that addition of pyrotinib to trastuzumab also significantly increased tpCR rate (22.0% vs 41.0%; P \< 0.0001), and the pCR rate was similar to trastuzumab + pertuzumab double target (39.3% for Neosphere and Peony). Based on these results, neoadjuvant therapy regimens with trastuzumab and TKI have been included in the 2022 CSCO guidelines. Of note, there were also differences in Hormone Receptor (HR) status in patients with HER2-positive breast cancer. After neoadjuvant chemotherapy combined with trastuzumab and pertuzumab double-target therapy, the pCR rate of HR-/HER2+ breast cancer was higher than HR+/HER2+ breast cancer. In contrast, a PHEDRA subgroup analysis showed that the addition of pyrotinib to trastuzumab more than doubled pCR rates in HR+/HER2+ patients (29.9% vs 12.2%) . In addition, in another adjunctive study of TKI drug neratinib, subgroup results also suggested that neratinib had a better effect on HR+/HER2+. Based on the above results, our research group proposed a hypothesis that TKI drugs may be more advantageous for HR+/HER2+ breast cancer. Therefore, our center intends to carry out a multi-center, randomized controlled, prospective clinical study to compare the efficacy of pyrotinib or pertuzumab combined with docetaxel, carboplatin and trastuzumab in neoadjuvant therapy for patients with HR+/HER2+ breast cancer, and to conduct a comparative study on the safety.
Interventions
COMBINATION_PRODUCTNeoadjuvant therapy: TCbHPy
Pyrotinib combined with docetaxel, carboplatin and trastuzumab (TCbHPy) for neoadjuvant therapy of HR+/HER2+ breast cancer
COMBINATION_PRODUCTNeoadjuvant therapy: TCbHP
Pertuzumab combined with docetaxel, carboplatin and trastuzumab (TCbHP) for neoadjuvant therapy of HR+/HER2+ breast cancer
Sponsors
The First Affiliated Hospital with Nanjing Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Masking description
This study is an open-design, multicenter, randomized controlled prospective clinical study with 80 patients. Subjects will be randomly assigned 1:1.
Intervention model description
The treatment regimen of the experimental group was pyrotinib combined with docetaxel, carboplatin and trastuzumab, while the treatment regimen of the control group was pertuzumab combined with docetaxel, carboplatin and trastuzumab (the control group was standard treatment). Surgical treatment was performed after 6 courses of neoadjuvant therapy
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Women aged 18-70 with breast cancer; 2. Pathologically confirmed unilateral invasive ductal carcinoma (with or without intraductal carcinoma components); 3. Proposed to receive neoadjuvant therapy; 4. Positive ER and/or PgR (defined as ≥10% positive immunohistochemical test); 5. HER2 positive (defined as IMMUNOHISTOchemical HER2 ++, or HER2 ++ and in situ hybridization (ISH) results in HER2 gene amplification); 6. There is no evidence of metastasis in clinical or imaging; 7. ECOG score 0 or 1; 8. White blood cell count ≥3.5×109/L, neutrophil count ≥2×109/L, platelet count ≥100×109/L and hemoglobin ≥90 g/L before neoadjuvant therapy; 9. Before neoadjuvant therapy, AST and ALT \< 1.5 times the upper limit of normal value, alkaline phosphatase \< 2.5 times the upper limit of normal value, total bilirubin \< 1.5 times the upper limit of normal value; Serum creatinine \< 1.5 times the upper limit of normal value; 10. LVEF≥55% on 2d echocardiography before neoadjuvant therapy; 11. Signed informed consent.
Exclusion criteria
1. Clinical or imaging suspicion of lateral breast malignancy has not been confirmed; 2. Prior malignancy (except basal cell carcinoma of the skin and carcinoma in situ of the cervix), including contralateral breast cancer; 3. The patient has been enrolled in other clinical trials; 4. Patients suffering from serious systemic diseases and/or uncontrollable infections cannot be enrolled in the study; 5. Severe cardiovascular and cerebrovascular diseases (e.g., unstable angina pectoris, chronic heart failure, uncontrolled hypertension \> 150/90mmHg, myocardial infarction or cerebrovascular accident) within the first 6 months of randomization; 6. Have a history of blood system diseases, especially platelet-related diseases; 7. Patients with previous intestinal inflammation, intestinal dysfunction, severe diarrhea and constipation; 8. People who are known to be allergic to chemotherapy drugs, targeted drugs or TKI drugs; 9. Women of childbearing age refuse contraception during treatment and within 8 weeks after completion of treatment; 10. Pregnant and lactation women; 11. positive pregnancy test before drug use after joining the test; 12. Mental illness, cognitive impairment, inability to understand the test protocol and side effects, inability to complete the test protocol and follow-up workers (systematic evaluation is required before the trial is enrolled); 13. Persons without personal freedom and independent capacity for civil conduct.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| tpCR rate (ypT0/is ypN0) | 1 month after surgery | Pathological complete response rate after neoadjuvant ( both breast and axillary lymph nodes, in which the breast may have residual carcinoma in situ) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| iDFS | 3 years | invasive Disease Free Survival |
| EFS | 3 years | Event Free Survival |
Countries
China
Contacts
Primary ContactJue Wang, Doctor
Backup ContactRui Chen, Master
Outcome results
None listed